{"content":[{"text":"Upcoming Milestones \n SY-1425: Oral RARa agonist","bbox":{"left":0.098039,"top":0.06867,"width":0.250489,"height":0.03492000000000001}},{"text":"Initiate randomized Phase 2 trial of SY-1425 in combination with venetoclax and \n azacitidine in the second half of 2021 in RARA-positive newly diagnosed AML patients \n who are not suitable candidates for standard intensive chemotherapy. \n Report initial data from the randomized Phase 2 trial in 2022.","bbox":{"left":0.147059,"top":0.119806,"width":0.7470509999999999,"height":0.070905}},{"text":"SY-2101: Oral arsenic trioxide (ATO)","bbox":{"left":0.098039,"top":0.206928,"width":0.32014,"height":0.016926999999999998}},{"text":"Initiate dose-confirmation study of SY-2101 in the second half of 2021. \n Report confirmatory dose and pharmacokinetic data in first half of 2022. \n Initiate Phase 3 trial in patients with newly diagnosed APL in 2022.","bbox":{"left":0.147059,"top":0.240072,"width":0.620701,"height":0.05291100000000004}},{"text":"SY-5609: Oral CDK7 inhibitor","bbox":{"left":0.098039,"top":0.3092,"width":0.255898,"height":0.016927000000000025}},{"text":"Report additional dose-escalation data, including clinical activity data, in the third \n quarter of 2021 from the ongoing Phase 1 trial of SY-5609 in patients with breast, \n colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid \n tumors of any histology harboring Rb pathway alterations. \n Initiate expansion portion of Phase 1 trial in the second half of 2021.","bbox":{"left":0.147059,"top":0.342344,"width":0.703479,"height":0.08889700000000006}},{"text":"Gene control discovery engine","bbox":{"left":0.098039,"top":0.447458,"width":0.26465800000000006,"height":0.016927000000000025}},{"text":"Nominate next development candidate in 2022.","bbox":{"left":0.147059,"top":0.480602,"width":0.409495,"height":0.016927000000000025}},{"text":"Recent Pipeline Highlights","bbox":{"left":0.098039,"top":0.513746,"width":0.247099,"height":0.016927000000000025}},{"text":"Syros began dosing patients in its Phase 3 trial evaluating SY-1425 in combination \n with azacitidine in RARA-positive patients with newly diagnosed HR-MDS. The double- \n blind, placebo-controlled trial is expected to enroll approximately 190 patients. Patients \n will be randomized 2:1 to receive SY-1425 in combination with azacitidine or placebo, \n respectively. The primary endpoint of the trial is complete response (CR) rate.","bbox":{"left":0.147059,"top":0.54689,"width":0.7513209999999999,"height":0.08889600000000009}},{"text":"Recent Corporate Highlights","bbox":{"left":0.098039,"top":0.652003,"width":0.26559600000000005,"height":0.016927000000000025}},{"text":"In January 2021, Syros completed an underwritten public offering of 5,400,000 shares \n of common stock, at a public offering price of $14.00 per share, resulting in gross \n proceeds of approximately $75.6 million, before underwriting discounts and \n commissions.","bbox":{"left":0.147059,"top":0.685147,"width":0.7438149999999999,"height":0.0709050000000001}},{"text":"First Quarter 2021 Financial Results","bbox":{"left":0.098039,"top":0.772269,"width":0.334243,"height":0.016927000000000025}},{"text":"Revenues were $4.8 million for the first quarter of 2021, consisting of $4.0 million in \n revenue recognized under Syros’ collaboration with Global Blood Therapeutics, Inc. \n (GBT) and $0.8 million recognized under its collaboration with Incyte Corporation \n (Incyte). Syros recognized $2.4 million in revenue in the first quarter of 2020, including \n $2.2 million under its collaboration with GBT and $0.2 million under its collaboration \n with Incyte. \n Research and development expenses were $20.0 million for the first quarter of 2021, \n as compared to $14.6 million for the first quarter of 2020. This increase was primarily","bbox":{"left":0.147059,"top":0.805413,"width":0.745911,"height":0.14287300000000003}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}